Literature DB >> 27256231

[Applying multiplex ligation-dependent probe amplification in the diagnosis of 5 cases with ornithine transcarbamylase deficiency].

Z W Gong1, L S Han, J Ye, W J Qiu, H W Zhang, Y G Yu, L L Liang, X L Gao, Y Wang, W J Ji, X F Gu.   

Abstract

OBJECTIVE: To detect large genomic deletions or duplications of ornithine transcarbamylase (OTC) gene by multiplex ligation-dependent probe amplification (MLPA).
METHOD: Thirty cases of suspected OTC deficiency (OTCD) patients based on tandem-mass spectrum results were recruited in Xinhua Hospital from 2012 to 2014, among whom 13 were male and 17 were female. Sanger sequencing of OTC gene revealed mutations in 23 cases. MLPA was performed in the patients whose previous Sanger sequencing failed to detect any disease-causing mutation. The samples were treated via the steps of DNA degeneration, the probe hybridization, connecting the hybridization probe, PCR amplification and capillary electrophoresis. The data were analyzed using Coffalyser software. RESULT: Abnormal MLPA results were found in 5 patients without mutation detected in previous Sanger sequencing. Patient 1, a 9-year old girl, had a heterozygous deletion of Exon 2-4. Patient 2, a male newborn, died 10 days after birth. The examination of the mother's sample by MLPA revealed a heterozygous duplication of exon 2-6. Patient 3, a 10-day old boy, was found to harbor a hemizygous deletion of exon 7-10. Patient 4, a 2-year old girl, harbored a heterozygous deletion of exon 1-4. The fifth patient died at the age of 6 years, and his mother carried a heterozygous duplication of exon 1-4.
CONCLUSION: MLPA can be helpful in detecting the OTC gene defects, particularly for OTCD patients without mutation detected by Sanger sequencing.

Entities:  

Mesh:

Year:  2016        PMID: 27256231     DOI: 10.3760/cma.j.issn.0578-1310.2016.06.010

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  5 in total

Review 1.  [Consensus on diagnosis and treatment of ornithine trans-carbamylase deficiency].

Authors: 
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-10-25

2.  A serendipitous journey to a promoter variant: The c.-106C>A variant and its role in late-onset ornithine transcarbamylase deficiency.

Authors:  Ashley Hertzog; Arthavan Selvanathan; Rebecca Halligan; Timothy Fazio; Gerard de Jong; Drago Bratkovic; Kaustuv Bhattacharya; Adviye Ayper Tolun; Bruce Bennetts; Katrina Fisk
Journal:  JIMD Rep       Date:  2022-04-12

3.  Clinical and molecular characteristics of 69 Chinese patients with ornithine transcarbamylase deficiency.

Authors:  Deyun Lu; Feng Han; Wenjuan Qiu; Huiwen Zhang; Jun Ye; Lili Liang; Yu Wang; Wenjun Ji; Xia Zhan; Xuefan Gu; Lianshu Han
Journal:  Orphanet J Rare Dis       Date:  2020-12-03       Impact factor: 4.123

4.  Clinical utility of exome sequencing in individuals with large homozygous regions detected by chromosomal microarray analysis.

Authors:  Aparna Prasad; Matthew A Sdano; Rena J Vanzo; Patricia A Mowery-Rushton; Moises A Serrano; Charles H Hensel; E Robert Wassman
Journal:  BMC Med Genet       Date:  2018-03-20       Impact factor: 2.023

5.  The Application of Next-Generation Sequencing (NGS) in Neonatal-Onset Urea Cycle Disorders (UCDs): Clinical Course, Metabolomic Profiling, and Genetic Findings in Nine Chinese Hyperammonemia Patients.

Authors:  Qingnv Zhou; Huafei Huang; Li Ma; Tianwen Zhu
Journal:  Biomed Res Int       Date:  2020-08-31       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.